Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Infection by closely related HIV strains possible

28.11.2002


A report of an individual infected with a second strain of HIV despite effective drug treatment following the first infection has researchers concerned.



"For the first time, we’ve shown it is possible for an individual to become infected with two closely related strains of HIV," says Bruce D. Walker, M.D., a grantee of the National Institute of Allergy and Infectious Diseases (NIAID) and a researcher at Massachusetts General Hospital and Harvard Medical School.

Published in this week’s issue of Nature, these findings underscore the challenges vaccine developers face in creating a broadly effective vaccine against HIV. The first HIV vaccines may not prevent infection altogether, but rather may prevent HIV from causing disease by limiting the virus’ ability to reproduce, explains Dr. Walker. This case shows that a hypothetical vaccine against one strain of HIV may not necessarily protect the vaccinee against other, closely related strains.


"The implications of superinfection for an individual with HIV/AIDS are not yet clear," says Anthony S. Fauci, M.D., NIAID’s director. "However, there is little doubt what these new data mean in terms of public health: It is imperative that safer sex be practiced during each encounter, even when both partners are HIV-infected," he adds.

The new case involves a person whose HIV infection was kept in check for many months during structured treatment interruption (STI). In STI, antiviral therapies are frequently given during the early, acute stage of infection, but halted after the immune system has had time to adapt to the virus. Often, as in this case, a patient’s immune system rebounds enough to keep HIV suppressed. "This patient’s immune response against HIV was really quite robust," says Dr. Walker. Thus, the researchers were perplexed when, after successfully suppressing HIV for close to one year, the patient’s viral load suddenly shot upwards. Despite several more attempts to interrupt therapy, the patient was unable to hold the virus to previously attained low levels.

To understand why STI stopped working for this individual, "We dissected the immune system in very fine detail," says Dr. Walker. First, he and his co-investigators examined HIV-made proteins taken from the patient at several points in time. They detected a difference between the amino acid sequence of the original infecting virus and the virus isolated after STI failed. Additional studies confirmed that the change resulted from infection by a second HIV strain well after the first infection.

The two strains differed in overall amino acid sequence by about 12 percent, "about what we’d expect for two strains in North America," notes Dr. Walker. In comparison, the sequence difference between strains of various major subtypes, or clades, of HIV is about 30 percent. Although superinfection by strains from different clades has been reported previously, this is the first published report of infection by two strains from the same clade.

The picture became still more sobering when the researchers compared only those HIV amino acid sequences targeted by the immune system. Here, the strains differed by 50 percent. Consequently, a large fraction of the immune cells that had been produced previously and that had successfully tamped down the first virus were unable to recognize and react to the second strain. "We were stunned," says Dr. Walker. "Essentially, the immune system was encountering two markedly different viruses."

The research did uncover a few bright spots, however. For instance, immune system cells called CD8+ T cells, appeared in new, strain-specific forms after the individual became infected with the second strain. This indicates an ability on the part of the CD8+ T cells to react appropriately to newly arrived HIV strains, even in conditions of chronic infection. Thus, researchers can remain cautiously optimistic that therapeutic immunization to create broader and more potent immune responses in persons with chronic HIV infection may one day be possible.


NIAID is a component of the National Institutes of Health (NIH), which is an agency of the Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

Reference: M Altfeld et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 240:434-39 (2002).

Anne Oplinger | EurekAlert!
Further information:
http://www.niaid.nih.gov/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Laser use for neurosurgery and biofabrication - LaserForum 2016 focuses on medical technology

27.09.2016 | Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

 
Latest News

New switch decides between genome repair and death of cells

27.09.2016 | Life Sciences

Nanotechnology for energy materials: Electrodes like leaf veins

27.09.2016 | Physics and Astronomy

‘Missing link’ found in the development of bioelectronic medicines

27.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>